GIBSON DUNN

Gibson Dunn Advises Apogee Therapeutics on $402.5 Million Offering of Common Stock

Firm News | March 26, 2026

Gibson Dunn represented Apogee Therapeutics, Inc. in a public offering of common stock that generated aggregate gross proceeds of approximately $402.5 million to Apogee.

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications.

Gibson Dunn regularly advises clinical-stage biotechnology companies on capital markets transactions in the life sciences sector.

The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Candice Johnson, Jasmine Vitug, and Anika Gidwani.

Related Capabilities

Capital Markets

Life Sciences

Related People

Ryan A. Murr

Branden C. Berns

Melanie E. Neary

Candice D. Johnson

Jasmine L. Vitug

Anika Gidwani

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**